SK164196A3 - Polynucleotide, pharmaceutical composition containing same and a vaccine - Google Patents

Polynucleotide, pharmaceutical composition containing same and a vaccine Download PDF

Info

Publication number
SK164196A3
SK164196A3 SK1641-96A SK164196A SK164196A3 SK 164196 A3 SK164196 A3 SK 164196A3 SK 164196 A SK164196 A SK 164196A SK 164196 A3 SK164196 A3 SK 164196A3
Authority
SK
Slovakia
Prior art keywords
crpv
hpv
dna
gene
papilloma virus
Prior art date
Application number
SK1641-96A
Other languages
English (en)
Slovak (sk)
Inventor
John J Donnelly
Margaret A Liu
Douglas Martinez
Donna L Montgomery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SK164196A3 publication Critical patent/SK164196A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
SK1641-96A 1994-06-30 1995-06-01 Polynucleotide, pharmaceutical composition containing same and a vaccine SK164196A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30
PCT/US1995/006915 WO1996000583A1 (en) 1994-06-30 1995-06-01 Polynucleotide vaccine for papillomavirus

Publications (1)

Publication Number Publication Date
SK164196A3 true SK164196A3 (en) 1997-08-06

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1641-96A SK164196A3 (en) 1994-06-30 1995-06-01 Polynucleotide, pharmaceutical composition containing same and a vaccine

Country Status (20)

Country Link
US (1) US5866553A (fi)
EP (1) EP0768893B1 (fi)
JP (1) JPH10501987A (fi)
CN (1) CN1156966A (fi)
AT (1) ATE233101T1 (fi)
AU (1) AU701973B2 (fi)
CA (1) CA2193365C (fi)
CZ (1) CZ375296A3 (fi)
DE (1) DE69529748T2 (fi)
ES (1) ES2191052T3 (fi)
FI (1) FI965224A0 (fi)
HU (1) HU220747B1 (fi)
IL (1) IL113817A (fi)
MX (1) MX9700229A (fi)
NO (1) NO965590L (fi)
NZ (1) NZ288045A (fi)
PL (1) PL180639B1 (fi)
SK (1) SK164196A3 (fi)
WO (1) WO1996000583A1 (fi)
ZA (1) ZA954641B (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
JP2001515468A (ja) * 1997-02-14 2001-09-18 メルク エンド カンパニー インコーポレーテッド ポリヌクレオチドワクチン製剤
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2328180A1 (en) * 1998-04-14 1999-10-21 Merck & Co., Inc. Needleless administration of polynucleotide formulations
EP1728865A1 (en) * 1998-09-04 2006-12-06 Aventis Pasteur Limited Treatment of cervical cancer
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
ATE276199T1 (de) * 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
ATE272410T1 (de) * 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
WO2000061184A2 (en) * 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
EP1372708B1 (en) * 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
PT1409012E (pt) * 2001-06-22 2009-05-11 Wistar Inst Métodos de indução de uma resposta imunitária citotóxica e composições de adenovírus recombinantes de símio úteis para esse efeito
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
AU2003297039B2 (en) 2002-12-13 2009-03-05 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP1720520B1 (en) * 2004-02-13 2010-06-09 Nod Pharmaceuticals, Inc. Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof
US20090041812A1 (en) * 2004-11-01 2009-02-12 Bell Steve J D Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
US8404244B2 (en) * 2005-02-01 2013-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
CN101293918B (zh) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
WO2008145021A1 (en) * 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
JP2016514672A (ja) * 2013-03-15 2016-05-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
WO1986005816A1 (en) * 1985-04-04 1986-10-09 Georgetown University Type-specific papillomavirus dna sequences and peptides
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
ATE165516T1 (de) * 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
DE122007000017I1 (de) * 1991-07-19 2007-07-26 Univ Queensland Impfstoffe gegen Papillomavirus
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
ES2201055T3 (es) * 1992-08-07 2004-03-16 Wyeth Vacunas de adenovirus recombinante.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
ES2191052T3 (es) 2003-09-01
MX9700229A (es) 1997-04-30
PL180639B1 (pl) 2001-03-30
CA2193365A1 (en) 1996-01-11
DE69529748T2 (de) 2003-10-16
CZ375296A3 (en) 1997-08-13
IL113817A0 (en) 1995-08-31
US5866553A (en) 1999-02-02
HU220747B1 (hu) 2002-05-28
DE69529748D1 (de) 2003-04-03
NZ288045A (en) 1998-08-26
CN1156966A (zh) 1997-08-13
NO965590L (no) 1997-02-28
WO1996000583A1 (en) 1996-01-11
PL317874A1 (en) 1997-04-28
NO965590D0 (no) 1996-12-27
FI965224A (fi) 1996-12-27
ZA954641B (en) 1996-01-26
CA2193365C (en) 2007-04-03
EP0768893A1 (en) 1997-04-23
ATE233101T1 (de) 2003-03-15
HU9603562D0 (en) 1997-02-28
AU2694595A (en) 1996-01-25
FI965224A0 (fi) 1996-12-27
AU701973B2 (en) 1999-02-11
HUT76446A (en) 1997-09-29
IL113817A (en) 2001-03-19
EP0768893B1 (en) 2003-02-26
JPH10501987A (ja) 1998-02-24

Similar Documents

Publication Publication Date Title
US5866553A (en) Polynucleotide vaccine for papillomavirus
Suzich et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
Peng et al. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway
Christensen et al. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
CA2342289C (en) Treatment of cervical cancer
US20040086527A1 (en) Protecting against canine oral papillonmavirus (COPV)
WO2021013071A1 (zh) 人乳头瘤病毒多价免疫原性组合物
US6174532B1 (en) L2 immunogenic peptides of papillomavirus
JP2002516291A (ja) パピローマウイルス・ウイルス様粒子による経口免疫感作
Fernando et al. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production
WO2008154867A1 (en) Material with immunogenicity
Liu et al. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses
JPH10503649A (ja) ポリヌクレオチド・ヘルペスウイルス・ワクチン
CN113278634B (zh) 一种预防和治疗默克尔细胞癌的新型疫苗
Yi et al. Recombinant bivalent vaccine against foot-and-mouth disease virus serotype O/A infection in guinea pig
Srinivasan et al. Targeting vaccinia virus-expressed secretory beta subunit of human chorionic gonadotropin to the cell surface induces antibodies
RU2173170C2 (ru) Полинуклеотидная вакцина для вируса папилломы
US7238672B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
Deng et al. The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro
AU719837B2 (en) Pharmaceuticals based on papillomaviruses
Moore Canine papillomavirus–a mucosal model of human disease
AU5013099A (en) Papillomavirus vaccine
Kwak Development of prophylactic human papillomavirus vaccines
AU4889102A (en) Papillomavirus vaccine